The Top 5 Biosimilars Articles for the Week of April 6

The Center for Biosimilars® recaps the top stories for the week of April 6, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of April 6, 2020.

Number 5: As the coronavirus disease (COVID-19) pandemic spreads, it will continue to affect the biopharmaceutical industry. Biosimilars are no exception, and the effect on their uptake and adoption will be multifaceted, according to ZS.

Number 4: Following close on the heels of its US approval for biosimilar rituximab, Pfizer has gained the European Commission’s nod and aims to launch in coming months.

Number 3: Self-insured companies could have saved between $407 million and $1.4 billion in 2018 had they switched completely from reference biologics, infliximab and filgrastim, to biosimilars, according to a report.

Number 2: Amid the coronavirus pandemic, the FDA issued guidance stressing the importance that manufacturers notify it of discontinuations and manufacturing interruptions so that the agency can implement contingency measures.

Number 1: The race to find a way to knock down the coronavirus pandemic has attracted companies with stakes in the biosimilar game. The winner could take all.

To read all of these articles and more, visit centerforbiosimilars.com.